Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

App aims to boost cancer patients' well-being at home

NCT ID NCT06379880

Symptom relief Sponsor: Centre Paul Strauss Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed trial tested a web-based remote monitoring platform called CONTINUUM+ CONNECT in 411 adults with metastatic breast, lung, colorectal, or prostate cancer. Patients used the platform to report symptoms and receive alerts, aiming to improve their physical health and quality of life compared to standard care. The study measured changes in quality-of-life scores after 3 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CONTINUUM+ CONNECT remote monitoring platform (digital device)
What this could lead to
If successful, this could show that remote monitoring helps cancer patients feel better and manage symptoms at home.
What could go wrong
This is a completed study, but it only measures quality of life over 3 months, not survival or cure. Results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

411 people

The number who actually took part.

Started

Apr 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients aged ≥ 18 years with a solid tumor (only breast, lung, colorectal, prostate cancer) at the metastatic stage followed on an outpatient basis; 2. Patients initiating oral and/or injectable anticancer treatment, whatever the line of treatment, administered on an outpatient basis including day hospitalization; 3. Patients who have given their written, free and informed consent; 4. Patients with life expectancy of more than 3 months; 5. Patients able to complete questionnaires according to the investigator's judgment, and to use the CONTINUUM+ CONNECT electronic application either alone or accompanied by a professional (home nurse); 6. Patients affiliated to a social security scheme or beneficiaries of such a scheme. Exclusion Criteria: 1. Patients receiving home hospitalization care or being hospitalized at the time of treatment initiation; 2. Patients receiving concomitant radiotherapy; 3. Patients using another remote monitoring application; 4. Patients enrolled in another clinical trial; 5. Patients protected by law.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm colorectal cancer colorectal neoplasm lung cancer lung carcinoma lung neoplasm metastatic prostate carcinoma Neoplasm Metastasis prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms Colorectal neoplasms Lung neoplasms Prostatic neoplasms

Contacts and locations

Locations

  • CHU de Saint-Etienne

    Saint-Priest-en-Jarez, 42270, France

  • Centre Hospitalier de Morlaix

    Morlaix, 29600, France

  • Centre Paul Strauss

    Strasbourg, 67033, France

  • Centre d'oncologie de Gentilly

    Nancy, 54100, France

  • Chu Dupuytren

    Limoges, 87042, France

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67091, France

  • Hôpitla privé des Côtes d'Armor - Centre CARIO-HPCA

    Plérin, 22190, France

  • Institut Jean Godinot

    Reims, 51100, France

  • Institut de Cancerologie de Lorraine

    Vandœuvre-lès-Nancy, De, 54519, France

  • Polyclinique de Blois

    Blois, 41260, France

  • Pôle Santé République

    Clermont-Ferrand, 63000, France

  • Sainte-Catherine, Institut du Cancer Avignon-Provence

    Avignon, 84918, France

  • centre Georges François Leclerc

    Dijon, 21079, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.